Multiplexed Methylation Profiles of Tumor Suppressor Genes and Clinical Outcome in Oligodendroglial Tumors

Overview

Journal Cancer Med

Specialty Oncology

Date 2016 Jul 2

PMID 27367901

Citations 3

Authors

Lu-Ting Kuo

Hsueh-Yi Lu

Chien-Chang Lee

Jui-Chang Tsai

Hong-Shiee Lai

Ham-Min Tseng

Meng-Fai Kuo

Yong-Kwang Tu

Affiliations

Soon will be listed here.

Abstract

Aberrant methylation has been associated with transcriptional inactivation of tumor-related genes in a wide spectrum of human neoplasms. The influence of DNA methylation in oligodendroglial tumors is not fully understood. Genomic DNA was isolated from 61 oligodendroglial tumors for analysis of methylation using methylation-specific multiplex ligation-dependent probe amplification assay (MS-MLPA). We correlated methylation status with clinicopathological findings and outcome. The genes found to be most frequently methylated in oligodendroglial tumors were RASSF1A (80.3%), CASP8 (70.5%), and CDKN2A (52.5%). Kaplan-Meier survival curve analysis demonstrated longer duration of progression-free survival in patients with 19q loss, aged less than 38 years, and with a proliferative index of less than 5%. Methylation of the ESR1 promoter is significantly associated with shorter duration of overall survival and progression-free survival, and that methylation of IGSF4 and RASSF1A is significantly associated with shorter duration of progression-free survival. However, none of the methylation status of ESR1, IGSF4, and RASSF1A was of prognostic value for survival in a multivariate Cox model. A number of novel and interesting epigenetic alterations were identified in this study. The findings highlight the importance of methylation profiles in oligodendroglial tumors and their possible involvement in tumorigenesis.

Citing Articles

A single-arm phase 2 study of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma.

Wills C, Mohan S, Nabavizadeh A, Patel T, Prior T, Mansour M Neurooncol Adv. 2025; 7(1):vdaf011.

PMID: 39944054 PMC: 11815343. DOI: 10.1093/noajnl/vdaf011.

Hemizygous deletion of cyclin-dependent kinase inhibitor 2A/B with p16 immuno-negative and methylthioadenosine phosphorylase retention predicts poor prognosis in IDH-mutant adult glioma.

Otsuji R, Hata N, Yamamoto H, Kuga D, Hatae R, Sangatsuda Y Neurooncol Adv. 2024; 6(1):vdae069.

PMID: 39022644 PMC: 11252564. DOI: 10.1093/noajnl/vdae069.

Astrocytoma progression scoring system based on the WHO 2016 criteria.

Li Z, Guan Y, Liu Q, Wang Y, Cui R, Wang Y Sci Rep. 2019; 9(1):96.

PMID: 30643174 PMC: 6331604. DOI: 10.1038/s41598-018-36471-4.

Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in oligodendroglial tumors.

Kuo L, Lu H, Lee C, Tsai J, Lai H, Tseng H Cancer Med. 2016; 5(8):1830-9.

PMID: 27367901 PMC: 4971911. DOI: 10.1002/cam4.762.

References

Nygren A, Ameziane N, Duarte H, Vijzelaar R, Waisfisz Q, Hess C . Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005; 33(14):e128. PMC: 1187824. DOI: 10.1093/nar/gni127. View

Kuo L, Kuo K, Lee M, Wei C, Scaravilli F, Tsai J . Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int J Cancer. 2009; 124(12):2872-9. DOI: 10.1002/ijc.24303. View

Schwarzenbach H, Chun F, Isbarn H, Huland H, Pantel K . Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients. J Cancer Res Clin Oncol. 2010; 137(5):811-9. DOI: 10.1007/s00432-010-0941-5. View

Gerson S . MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004; 4(4):296-307. DOI: 10.1038/nrc1319. View

Alonso M, Bello M, Gonzalez-Gomez P, Arjona D, Lomas J, de Campos J . Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet. 2003; 144(2):134-42. DOI: 10.1016/s0165-4608(02)00928-7. View

Kikuchi S, Yamada D, Fukami T, Maruyama T, Ito A, Asamura H . Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma. Cancer. 2006; 106(8):1751-8. DOI: 10.1002/cncr.21800. View

Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S . Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med. 2010; 8:86. PMC: 2955578. DOI: 10.1186/1479-5876-8-86. View

Stephen J, Chen K, Shah V, Havard S, Kapke A, Lu M . DNA hypermethylation markers of poor outcome in laryngeal cancer. Clin Epigenetics. 2011; 1(1-2):61-69. PMC: 3037188. DOI: 10.1007/s13148-010-0005-3. View

Brock M, Hooker C, Ota-Machida E, Han Y, Guo M, Ames S . DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008; 358(11):1118-28. DOI: 10.1056/NEJMoa0706550. View

10.

Uhlmann K, Rohde K, Zeller C, Szymas J, Vogel S, Marczinek K . Distinct methylation profiles of glioma subtypes. Int J Cancer. 2003; 106(1):52-9. DOI: 10.1002/ijc.11175. View

11.

Heegaard S, Sommer H, Broholm H, Broendstrup O . Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer. 1995; 76(10):1809-13. DOI: 10.1002/1097-0142(19951115)76:10<1809::aid-cncr2820761020>3.0.co;2-i. View

12.

Livide G, Epistolato M, Amenduni M, Disciglio V, Marozza A, Mencarelli M . Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA. Pathol Oncol Res. 2012; 18(3):703-12. DOI: 10.1007/s12253-012-9498-8. View

13.

Coons S, Johnson P, Pearl D . The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery. 1997; 41(4):878-84; discussion 884-5. DOI: 10.1097/00006123-199710000-00021. View

14.

Peters I, Rehmet K, Wilke N, Kuczyk M, Hennenlotter J, Eilers T . RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer. 2007; 6:49. PMC: 1939711. DOI: 10.1186/1476-4598-6-49. View

15.

Jeuken J, Cornelissen S, Vriezen M, Dekkers M, Errami A, Sijben A . MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest. 2007; 87(10):1055-65. DOI: 10.1038/labinvest.3700664. View

16.

Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, Benouaich-Amiel A . Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer. 2006; 107(8):1891-7. DOI: 10.1002/cncr.22211. View

17.

Bol G, Suijkerbuijk K, Bart J, Vooijs M, van der Wall E, van Diest P . Methylation profiles of hereditary and sporadic ovarian cancer. Histopathology. 2010; 57(3):363-70. DOI: 10.1111/j.1365-2559.2010.03642.x. View

18.

Issa J, Baylin S, Herman J . DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia. 1997; 11 Suppl 1:S7-11. View

19.

Schmidt E, Ichimura K, Reifenberger G, Collins V . CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 1994; 54(24):6321-4. View

20.

Wolter M, Reifenberger J, Blaschke B, Ichimura K, Schmidt E, Collins V . Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J Neuropathol Exp Neurol. 2002; 60(12):1170-80. DOI: 10.1093/jnen/60.12.1170. View